# Oxford Science Enterprises

> Oxford Science Enterprises is a VC fund backing Biotechnology. See 119 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Oxford, United Kingdom
- Total investments: 119
- Last investment: Feb 2025
- Lead investor: 34%
- Fund size: $337M
- Last fund: Jul 2022
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/oxford-science-enterprises/
- X (Twitter): https://twitter.com/OxfordSciEnt
- Website: https://oxfordscienceenterprises.com/

Oxford Science Enterprises is a VC fund in Oxford focused on Biotechnology and Health Care. Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.

## Contacts

5 contacts available for Oxford Science Enterprises. Shizune tracks 9 team members at Oxford Science Enterprises. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/oxford-science-enterprises?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $1.1M–$11M |
| Series A | $6.3M–$42M |
| Series B | $8.5M–$100M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 24 | 20% |
| Health Care | 23 | 19% |
| Software | 12 | 10% |
| Medical | 10 | 8% |
| Life Science | 10 | 8% |

96 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 39 | 33% |
| Seed | 29 | 24% |
| Series B | 18 | 15% |
| Funding Round | 8 | 7% |
| Venture - Series Unknown | 6 | 5% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 66 | 55% |
| United States | 3 | 3% |
| The Netherlands | 1 | 1% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Alexis Dormandy | Chief Executive Officer | 1 | https://shizune.co/investors/profile/alexis-dormandy |
| Alexis Zervoglos | Senior Partner (Technology) | 3 | https://shizune.co/investors/profile/alexis-zervoglos |
| Claire Brown | Partner ( Life Sciences) | 3 | https://shizune.co/investors/profile/claire-brown |
| David Norwood | Chairman | 0 | https://shizune.co/investors/profile/david-norwood |
| Jim Wilkinson | Chief Financial Officer | 0 | https://shizune.co/investors/profile/jim-wilkinson-4045 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Salience Labs | Salience Labs is building a hybrid photonic-electronic chip for AI. We have designed a massively parallel, ultra-high-throughput Photonic Tensor Processing Unit. Photonics allows data to be modulated at up to 100 GHZ, and allows for high levels of parallelization using multiplexing. We integrate this photonic unit into a SoC architecture designedto exploit its high throughput for AI inference. Salience Labs technology is based on decades of research collaboration between Oxford University and the University of Münster, Germany. | $30M | Series A | Feb 07, 2025 |  |
| Neu Health | Neu Health enables clinicians, caregivers, and patients to tackle this growing challenge with cutting-edge digital technologies. | $2M | Seed | Jan 29, 2025 |  |
| FluoRok | FluoRok is revolutionizing the way fluorochemicals are produced globally. | $10.3M | Seed | Sep 23, 2024 |  |
| Iota Sciences | Iota Sciences is develops technologies with unique capabilities to advance discovery into cell biology. |  | Venture - Series Unknown | Jul 31, 2024 |  |
| natcap | natcap is a nature intelligence company that provides report and act on impacts and dependencies on nature. | $10M | Series A | Jul 03, 2024 |  |
| PQShield | Formed as a spinout of the University of Oxford by cryptography researchers and specialists, PQShield has unrivalled domain expertise in the design and implementation of quantum-resistant cryptography for software and hardware applications. PQShield is a major contributing participant to the National Institute of Standards and Technology (NIST)Post-Quantum Standardisation Process. At PQShield, we help customers transition their product lines from legacy RSA and Elliptic Curve cryptography to quantum-secure standards by offering ready-made and tailored IP for secure elements, IoT firmware, PKI and server technologies, and end-user applications." | $37M | Series B | Jun 20, 2024 |  |
| Fractile | Fractile is building chips to run large language models two orders of magnitude faster. Existing hardware is good for training LLMs, but very poorly suited to subsequent inference of the trained model, which is increasingly the dominant workload. A network’s weights need to be moved onto a chip once per word generated, and this movement takes a fewhundred times longer than the subsequent computations themselves. Fractile’s revolutionary approach to fusing computation with memory eliminates this bottleneck, and can scale to allow running the world’s largest models at a global scale. | $14.8M | Seed | Jun 18, 2024 |  |
| Amber Therapeutics | Amber Therapeutics develops the next-generation of bioelectrical therapies that can sense and adapt as well as stimulate, with the potential to radically improve clinical outcomes in patients with functional disorders of the peripheral nervous system. | $101.8M | Series A | Jun 09, 2024 |  |
| Beacon Therapeutics | Beacon Therapeutics is an ophthalmic gene therapy company that restores and improves vision and rare retinal diseases that result in blindness. | $170M | Series B | Jun 03, 2024 |  |
| Greywolf Therapeutics | Grey Wolf Therapeutics is a UK-based drug discovery biotechnology company focused on immuno-oncology. Rather than targeting the immune system, Grey Wolf’s approach is to directly alter the tumour cells, illuminating them for attack and destruction by the immune system. THey are targeting the endoplasmic reticulum aminopeptidases (ERAP) 1 and 2 inthe antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells, thus dramatically increasing tumour visibility and extending the reach of immunotherapy in oncology. Grey Wolf is working with leading academic and commercial drug discovery partners to deliver a clinical candidate against a strongly validated target. | $50M | Series B | May 23, 2024 |  |

10 of 119 investments shown.

## Co-investors
- [Oxford Science Enterprises](https://shizune.co/investors/profile/oxford-sciences-innovation) — VC Fund, 120 deals together
- [Parkwalk Advisors](https://shizune.co/investors/profile/parkwalk-advisors) — VC Fund, 15 deals together
- [University of Oxford](https://shizune.co/investors/profile/university-of-oxford) — VC Fund, 15 deals together
- [IP Group](https://shizune.co/investors/profile/ip-group-plc) — VC Fund, 13 deals together
- [Oxford Investment Consultants LLP](https://shizune.co/investors/profile/oxford-technology-and-innovations-fund) — VC Fund, 13 deals together
- [Oxford University Innovation](https://shizune.co/investors/profile/oxford-university-innovation) — VC Fund, 11 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [Fuel Ventures](https://shizune.co/investors/profile/fuel-ventures-fund) — VC Fund
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund

## Featured in investor lists
- [All Investors in United Kingdom](https://shizune.co/investors/investors-united-kingdom)
- [All VC Funds in United Kingdom](https://shizune.co/investors/vc-funds-united-kingdom)
- [Health Care Investors in United Kingdom](https://shizune.co/investors/health-care-investors-united-kingdom)
- [Health Care VC Funds in United Kingdom](https://shizune.co/investors/health-care-vc-funds-united-kingdom)
- [Health Care Investors in Europe](https://shizune.co/investors/health-care-investors-europe)
- [Health Care VC Funds in Europe](https://shizune.co/investors/health-care-vc-funds-europe)

## FAQ

### What does Oxford Science Enterprises invest in?

Oxford Science Enterprises invests primarily in Biotechnology, Health Care and Software startups, most often at Series A and Seed stage. Most of the 119 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Oxford Science Enterprises's check size?

Oxford Science Enterprises typically joins rounds of $1.1M–$11M at Seed, $6.3M–$42M at Series A and $8.5M–$100M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Oxford Science Enterprises participates in.

### How do I contact Oxford Science Enterprises?

Public channels for Oxford Science Enterprises include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Oxford Science Enterprises?

The team at Oxford Science Enterprises includes Alexis Dormandy (Chief Executive Officer), Alexis Zervoglos (Senior Partner (Technology)) and Claire Brown (Partner ( Life Sciences)), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co